Senores Pharmaceuticals is a global maker of complex generic medicines that has transformed itself from a trader of sourced products into a manufacturer with its own factories, drug approvals and research labs - a pivot completed in the 18 months leading into early 2026. Founded in India in 2017 and listed in 2024, the company now sells into more than 40 countries from two continents, with a philosophy of hunting for niche, under-served molecules where large pharma companies have little presence and then taking those products from idea to pharmacy shelf with what management calls a 100% track record. That approach - find a gap, develop the drug, own the factory, and partner for distribution - repeats across every market it enters.
Business segments
A single manufacturing engine expressed through three customer-facing channels - regulated-markets generics and CDMO services, emerging-markets formulations, and India hospital injectables - all fed by an in-house API and R&D backbone.
1. Regulated-markets generics and CDMO: the company’s largest and fastest-growing channel
A portfolio of 51 owned drug approvals, a factory in Atlanta, and long-term marketing deals with established pharma companies turn niche molecules into recurring revenue in the US, Canada and the UK.
- Owns the drug approvals - the company holds 51 approved ANDAs (abbreviated new drug applications, the licences needed to sell a generic in the US) covering more than 150 product strengths, more than double the 22 it held a year earlier, with 21 ANDAs already launched commercially and another 30 approved and waiting to launch.
- Bought as well as built - 35 of those ANDAs were acquired, including a basket of 14 from Dr. Reddy’s Laboratories and individual products from Teva and Wockhardt, so the pipeline grew faster than internal development alone could manage.
- Sells to the government, not just the pharmacy - a large part of the portfolio is designed for US government contracts and controlled substances, and a joint venture called Amerisyn formed in April 2026 gives direct access to federal, Veterans Affairs and military procurement programmes with fixed-price, long-term contracts that suffer less price erosion than the retail channel.
- Also a contract manufacturer - the CDMO and CMO arm develops and makes drugs for other pharma companies across more than 40 products in nine countries, earning tech-transfer fees, service income and profit shares under multi-year agreements that create steady cash flows alongside the company’s own branded launches.
2. Emerging-markets formulations: a broad portfolio sold through local partners
Nearly 1,400 products - from registered drugs to filed applications - reach over 40 countries through four go-to-market models, all manufactured at a single WHO-approved plant in Gujarat.
- Four ways to market - the business sells through distributors who put their own brand on the product, supplies other Indian pharma companies directly, acts as a CDMO for them, and is building an own-brand channel, so it can serve a country however the local market works.
- Regulated-market molecules, emerging-market positioning - products such as Apixaban, Tofacitinib and Sacubitril plus Valsartan have received marketing approvals, bringing drugs typically sold in the US and Europe into markets with less competition.
- One factory, many regulators - the Chhatral facility near Ahmedabad spans 379,000 square feet with 12 manufacturing lines across oral solids, liquids, injectables and ORS, and holds approvals from the health authorities of 10 countries including the Philippines, Nigeria, Kenya and Peru.
- Turning cash-flow positive - the segment reached an EBITDA margin of 18-19% in the fourth quarter of FY26 after shifting toward higher-value niche molecules and refining its country-by-country sales approach.
3. India branded injectables: a hospital-supply business built from scratch
Launched in August 2022, this channel delivers life-saving injectable drugs directly to Indian hospitals, cutting out middle-tier distributors.
- Direct to the hospital - the business works through regional distributors and direct hospital arrangements, bypassing mid-level wholesalers to build relationships with marquee multi-specialty and specialty hospitals.
- Small field force, fast growth - with 104 sales employees and 60 launched products, revenue grew nearly five times in FY26 to roughly INR40 crores, and the company aims for a pan-India presence by the end of the financial year.
- Made and bought - some products come from the company’s own WHO-GMP-approved Chhatral plant, while the rest are sourced from reputable Indian injectable manufacturers, keeping capital requirements low while the portfolio expands.
API manufacturing and R&D: the shared engine that feeds every channel
Seventeen active pharmaceutical ingredients made in-house and a four-site R&D network supply the molecules and the product pipeline that the three commercial channels depend on.
- Complex chemistry in-house - the API development lab is equipped for reactions including hydrogenation, Grignard and Friedel-Crafts, giving the company the ability to work on difficult molecules rather than relying on outside labs.
Group structure and partners
A holding company in India sits above a web of US and Indian subsidiaries, each with a distinct role - intellectual property, US manufacturing, emerging-markets production, and government-market access - while marketing partners handle distribution.
- Senores Pharmaceuticals Inc. holds the IP - this wholly owned US subsidiary, incorporated in 2021, owns the ANDA approvals and manages the marketing-partner agreements that generate revenue in regulated markets.
- Havix Group runs the Atlanta plant - doing business as Aavis Pharmaceuticals, this US subsidiary operates the FDA-approved manufacturing facility, with Senores having raised its stake from roughly 50% to 73% through a series of acquisitions during 2025.
- Ratnatris and Apnar Pharma expand manufacturing in India - Ratnatris (69% owned, acquired 2023) serves the emerging-markets business, while Apnar Pharma (75% owned, acquired January 2026) brings a USFDA, UK MHRA and Health Canada-approved plant with five ANDAs and a combined addressable market of about USD 722 million.
- Amerisyn and Zoraya open US government and commercial doors - Amerisyn (70% joint venture, formed March 2026) provides access to federal procurement, while Zoraya (51% step-down subsidiary, formed October 2025) manages full-cycle commercialisation with a team that has over a decade of US sales and marketing experience.